Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Return on Capital Employed (2016 - 2025)

Sangamo Therapeutics has reported Return on Capital Employed over the past 15 years, most recently at 3.82% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 3.82% for Q4 2025, down 211.0% from a year ago — trailing twelve months through Dec 2025 was 3.82% (down 211.0% YoY), and the annual figure for FY2025 was 3.17%, down 199.0%.
  • Return on Capital Employed for Q4 2025 was 3.82% at Sangamo Therapeutics, down from 2.54% in the prior quarter.
  • Over the last five years, Return on Capital Employed for SGMO hit a ceiling of 0.17% in Q1 2021 and a floor of 3.82% in Q4 2025.
  • Median Return on Capital Employed over the past 5 years was 0.92% (2023), compared with a mean of 1.35%.
  • Biggest five-year swings in Return on Capital Employed: crashed -292bps in 2024 and later surged 215bps in 2025.
  • Sangamo Therapeutics' Return on Capital Employed stood at 0.3% in 2021, then plummeted by -46bps to 0.43% in 2022, then crashed by -339bps to 1.89% in 2023, then increased by 9bps to 1.71% in 2024, then tumbled by -123bps to 3.82% in 2025.
  • The last three reported values for Return on Capital Employed were 3.82% (Q4 2025), 2.54% (Q3 2025), and 1.42% (Q2 2025) per Business Quant data.